Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 7, 2009

Francis Collins Confirmed as New NIH Director

  • The U.S. Senate today confirmed Francis S. Collins, M.D., Ph.D., as the new director of the NIH. President Barack Obama had nominated Dr. Collins for the position in early July.

    “This is a new day for healthcare in the United States,” says Sharon F. Terry, president and CEO of the Genetic Alliance in Washington, DC. “Dr. Collins understands that he needs to integrate all this fabulous discovery, biomedical, and clinical research into transformative health solutions. No one will be left out.”

    Dr. Collins is a physician-geneticist best known for his leadership of the Human Genome Project and his discoveries of disease genes. He served as director of the National Human Genome Research Institute (NHGRI) from 1993 to 2008.

    Dr. Collins received a B.S. in chemistry from the University of Virginia, a Ph.D. in physical chemistry from Yale University, and an M.D. with Honors from the University of North Carolina.

    Prior to coming to NIH he spent nine years on the faculty of the University of Michigan, where he was an investigator at the Howard Hughes Medical Institute.  He has been elected to the Institute of Medicine and the National Academy of Sciences and was awarded the Presidential Medal of Freedom in November 2007.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »